High ZNF521 expression was associated with poor prognosis in gastric cancer (overall survival [OS]: HR = 1.79, 95% CI = 1.43–2.24, P = 3.1 × 10−7; progression-free survival (PFS): HR = 1.72, 95% CI = 1.35–2.2, P = 1.2 × 10−5; post-progression survival (PPS): HR = 1.94, 95% CI = 1.48–2.56, P = 1.4 × 10−6; Figures 2(e)–2(g)). The gene discussed is ZNF521; the disease is gastric cancer.